US4291013A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Medicinally useful, shaped mass of collagen resorbable in the body
Assignee: Merck Patent GmbH
•
Filing: 1979-10-09
•
Granted: 1981-09-22
•
Expires: 1999-10-09
Abstract
Abstract A shaped mass resorbable in the body, comprises collagen and a bioresorbable binding agent for collagen, the binding agent being selected, e.g., from polymers of C 2-16 α-hydroxyalkanoic acids, polymers of natural amino acids, hydrolyzed collagen or hydrolyzed elastin.
Inventors
- 👤 Helmut Wahlig
- 👤 Elvira Dingeldein
- 👤 Dietrich Braun
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-22 18:35
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/50; A61L27/58; A61L15/00; A61L15/16; A61L15/22; A61L15/32; A61L15/325; A61L27/14; A61L27/22; A61L27/24; A61L27/26; A61L27/40; A61L27/44; A61L27/46; A61L27/54; A61L2300/00; A61L2300/40; A61L2300/404; A61L2300/406
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
137 words
A collagen based drug delivery system which is resorbable in the body, is sterilized and has been compacted into the shape of a tablet, spheroid, foil, pipe, plate, fiber, granule, strand or tube implantable into the body, by the application of heat of a temperature of 130°-200° C., optionally also with application of pressure of 300-1200 bar, with extrusion, with injection molding or with sintering and which, upon administration to the body, essentially maintains its shape and effects a retarded liberation of the drug, comprising 0.2-20 weight percent of a pharmacologically active drug material, 1-25 weight percent of a bioresorbable binding agent for collagen, and the balance being finely ground collagen, the binding agent consisting essentially of a co- or homopolymer of lactide or glycolide or a co- or a homopolymer of a C 2-16 α-hydroxyalkanoic acid.
Claim 2
Dependent Claim
137 words
A collagen based drug delivery system which is resorbable in the body, is sterilized and has been compacted into the shape of a tablet, spheroid, foil, pipe, plate, fiber, granule, strand or tube implantable into the body, by the application of heat of a temperature of 130°-200° C., optionally also with application of pressure of 300-1200 bar, with extrusion, with injection molding or with sintering and which, upon administration to the body, essentially maintains its shape and effects a retarded liberation of the drug, comprising 0.2-20 weight percent of a pharmacologically active drug material, 1-25 weight percent of a bioresorbable binding agent for collagen, and the balance being finely ground collagen, the binding agent consisting essentially of a co- or homopolymer of lactide or glycolide or a co- or a homopolymer of a C 2-16 α-hydroxyalkanoic acid.
Claim 3
Dependent Claim
20 words
The resorbable drug delivery system of claim 1, further comprising 0.1-40% by weight of the resorbable mass of calcium phosphate.
Claim 4
Dependent Claim
27 words
The resorbable drug delivery system of claim 1, wherein the binding agent is a copolymer of lactide and glycolide containing 10-30 mole % of glycolic acid units.
Claim 5
Dependent Claim
40 words
A method of administering a pharmacologically active material to a patient in need of treatment with the active material which comprises administering an effective amount of the active material in the form of a drug delivery system of claim 1.
Claim 6
Dependent Claim
13 words
The method of claim 4, wherein the administration is during a surgical procedure.
Claim 7
Dependent Claim
39 words
The resorbable drug delivery system of claim 1, comprising 3-10 wt. % of the binding agent based on the total amount of collagen and binding agent; and 1-10% by weight of the resorbable mass of the pharmacolgically active material.
Claim 8
Dependent Claim
20 words
The resorbable drug delivery system of claim 6 further comprising 0.1-40% by weight of the resorbable mass of calcium phosphate.
References Cited (Backward Citations)
US3126884A
Cited
CH139949A
Cited
CH141238A
Cited
CH144375A
Cited
US2967802A
Cited
US3322632A
Cited
US3478146A
Cited
US3400199A
Cited
FR1441817A
Cited
US3435117A
Cited
US3435110A
Cited
US3469003A
Cited
US3628974A
Cited
US3458397A
Cited
GB1213054A
Cited
US3443261A
Cited
US3608071A
Cited
US3551560A
Cited
US3563925A
Cited
US3639577A
Cited
US3823212A
Cited
GB1298223A
Cited
US3790507A
Cited
US3887699A
Cited
US3773919A
Cited
US3821371A
Cited
US3691281A
Cited
US3855638A
Cited
US3846542A
Cited
US3703575A
Cited
US3772432A
Cited
US3787900A
Cited
US3867190A
Cited
US3767437A
Cited
US3808606A
Cited
US4016252A
Cited
US3925545A
Cited
US3991766A
Cited
US3976071A
Cited
US4141864A
Cited
US4051598A
Cited
US3918100A
Cited
US4032993A
Cited
US3949073A
Cited
US4131650A
Cited
US4192021A
Cited
DE2620891B2
Cited
GB1541793A
Cited
DE2620890A1
Cited
US4202055A
Cited
DE2620907B2
Cited
US4177524A
Cited
US4191743A
Cited
US4191740A
Cited
US4239113A
Cited
US4156943A
Cited
US4164559A
Cited
US4195366A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-09-21 | 1985-03-23 | 1985-09-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-09-21 | 1989-03-23 | 1989-09-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-09-21 | 1993-03-23 | 1993-09-22 | $7700.00 | Window Closed / Lapsed |